Literature DB >> 30018079

Structure of an extended β3 integrin.

Dongwen Zhou1, Aye Myat Myat Thinn1,2, Yan Zhao1,3, Zhengli Wang1, Jieqing Zhu1,2.   

Abstract

Cells use adhesion receptor integrins to communicate with their surroundings. Integrin activation and cellular signaling are coupled with change from bent to extended conformation. β3 integrins, including αIIbβ3, which is essential for the function of platelets in hemostasis and thrombosis, and αVβ3, which plays multiple roles in diverse cell types, have been prototypes in understanding integrin structure and function. Despite extensive structural studies, a high-resolution integrin structure in an extended conformation remains to be determined. The human β3 Leu33Pro polymorphism, located at the PSI domain, defines human platelet-specific alloantigens 1a and 1b (HPA-1a/b), immune response to which is a cause of posttransfusion purpura and fetal/neonatal alloimmune thrombocytopenia. Leu33Pro substitution has also been suggested to be a risk factor for thrombosis. Here we report the crystal structure of the β3 headpiece in either Leu33 or Pro33 form, both of which reveal intermediate and fully extended conformations coexisting in 1 crystal. These were used to build high-resolution structures of full-length β3 integrin in the intermediate and fully extended states, agreeing well with the corresponding conformations observed by electron microscopy. Our structures reveal how β3 integrin becomes extended at its β-knee region and how the flexibility of β-leg domains is determined. In addition, our structures reveal conformational changes of the PSI and I-EGF1 domains upon β3 extension, which may affect the binding of conformation-dependent anti-HPA-1a alloantibodies. Our structural and functional data show that Leu33Pro substitution does not directly alter the conformation or ligand binding of β3 integrin.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30018079      PMCID: PMC6117741          DOI: 10.1182/blood-2018-01-829572

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  71 in total

1.  EDTA-induced changes in platelet structure and function: clot retraction.

Authors:  J G White
Journal:  Platelets       Date:  2000-02       Impact factor: 3.862

2.  Modulation of integrin activation and signaling by α1/α1'-helix unbending at the junction.

Authors:  Chuanmei Zhang; Jiafu Liu; Xiuli Jiang; Nada Haydar; Can Zhang; Hu Shan; Jieqing Zhu
Journal:  J Cell Sci       Date:  2013-10-21       Impact factor: 5.285

3.  Intact alphaIIbbeta3 integrin is extended after activation as measured by solution X-ray scattering and electron microscopy.

Authors:  Edward T Eng; Benoit J Smagghe; Thomas Walz; Timothy A Springer
Journal:  J Biol Chem       Date:  2011-08-09       Impact factor: 5.157

4.  Shear stress augments the enhanced adhesive phenotype of cells expressing the Pro33 isoform of integrin beta3.

Authors:  K Vinod Vijayan; Trevor C Huang; Yan Liu; Aubrey Bernardo; Jing Fei Dong; Pascal J Goldschmidt-Clermont; B Rita Alevriadou; Paul F Bray
Journal:  FEBS Lett       Date:  2003-04-10       Impact factor: 4.124

5.  iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM.

Authors:  T Geoff G Battye; Luke Kontogiannis; Owen Johnson; Harold R Powell; Andrew G W Leslie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

6.  Focal adhesions are sites of integrin extension.

Authors:  Janet A Askari; Christopher J Tynan; Stephen E D Webb; Marisa L Martin-Fernandez; Christoph Ballestrem; Martin J Humphries
Journal:  J Cell Biol       Date:  2010-03-15       Impact factor: 10.539

7.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

8.  Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin beta 3 subunit.

Authors:  S Honda; Y Tomiyama; A J Pelletier; D Annis; Y Honda; R Orchekowski; Z Ruggeri; T J Kunicki
Journal:  J Biol Chem       Date:  1995-05-19       Impact factor: 5.157

9.  Modeling and molecular dynamics of HPA-1a and -1b polymorphisms: effects on the structure of the β3 subunit of the αIIbβ3 integrin.

Authors:  Vincent Jallu; Pierre Poulain; Patrick F J Fuchs; Cecile Kaplan; Alexandre G de Brevern
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  6 in total

1.  Autonomous conformational regulation of β3 integrin and the conformation-dependent property of HPA-1a alloantibodies.

Authors:  Aye Myat Myat Thinn; Zhengli Wang; Dongwen Zhou; Yan Zhao; Brian R Curtis; Jieqing Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-12       Impact factor: 11.205

2.  High-resolution mapping of the polyclonal immune response to the human platelet alloantigen HPA-1a (PlA1).

Authors:  Huiying Zhi; Maria Therese Ahlen; Aye Myat Myat Thinn; Hartmut Weiler; Brian R Curtis; Bjørn Skogen; Jieqing Zhu; Peter J Newman
Journal:  Blood Adv       Date:  2018-11-13

3.  Current Anti-HPA-1a Standard Antibodies React with the β3 Integrin Subunit but not with αIIbβ3 and αvβ3 Complexes.

Authors:  Behnaz Bayat; Annalena Traum; Heike Berghöfer; Silke Werth; Jieging Zhu; Gregor Bein; Ulrich J Sachs; Sentot Santoso
Journal:  Thromb Haemost       Date:  2019-10-06       Impact factor: 5.249

4.  Naturally occurring point mutation Cys460Trp located in the I-EGF1 domain of integrin β3 alters the binding of some anti-HPA-1a antibodies.

Authors:  Sarah Theresa Holzwarth; Behnaz Bayat; Jieqing Zhu; Roongaroon Phuangtham; Lars Fischer; Doris Boeckelmann; Lida Röder; Heike Berghöfer; Silke Schmidt; Gregor Bein; Sentot Santoso
Journal:  Transfusion       Date:  2020-08-08       Impact factor: 3.157

Review 5.  Structural Immunology of Complement Receptors 3 and 4.

Authors:  Thomas Vorup-Jensen; Rasmus Kjeldsen Jensen
Journal:  Front Immunol       Date:  2018-11-26       Impact factor: 7.561

6.  Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage.

Authors:  Qianying Lv; Xinli Han; Jiajia Ni; Qianqian Ma; Rufeng Dai; Jiaojiao Liu; Jialu Liu; Yihui Zhai; Qian Shen; Li Sun; Haimei Liu; Jia Rao; Hong Xu
Journal:  Cell Death Dis       Date:  2022-10-13       Impact factor: 9.685

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.